Skip to content

Shattuck Labs, Inc. STTK Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s proceeds from warrant exercises?
Shattuck Labs, Inc. (STTK) reported proceeds from warrant exercises of $5.44M in Q1 2026.
What does proceeds from warrant exercises mean?
This metric measures the cash inflows received by the company when holders of outstanding warrants exercise their right to purchase common stock at a predetermined price. It serves as a source of non-dilutive or secondary capital that strengthens the company's liquidity position. Investors analyze this to assess the potential for future equity dilution and the conversion of derivative instruments into common shares.